Brief: BriaCell Enrollment Pace Accelerating In Phase 3 Clinical Study In Advanced Metastatic Breast Cancer (Bria-ABC)
22/04/2025 14:10
April 22 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL ENROLLMENT PACE ACCELERATING IN PHASE 3 CLINICAL STUDY IN ADVANCED METASTATIC BREAST CANCER (BRIA-ABC) BRIACELL THERAPEUTICS CORP - EXPECTS TO COMPLETE ENROLLMENT IN LATE 2025 OR EARLY 2026 BRIACELL THERAPEUTICS CORP: MAY REPORT TOP LINE DATA AS EARLY AS H1-2026 Source text: ID:nGNX7c5vzY Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study